Select Projects
-
AfrEVacc African-European HIV Vaccine Development Network -
AGEhiV Comorbidity and aging with HIV -
AIDS Fonds HIV Diagnostics Sustainable Diagnostics in Africa -
Antimicrobial resistance in TB Selection of appropriate treatment and infection control measures by integrated... -
ART-A Affordable Resistance tests for Africa -
Biomarkers Characterisation of novel microbicide safety biomarkers in East and South... -
CAD4TBCloud CAD4TBCloud -
CAGE-TB Automated smartphone-based cough audio classification for rapid tuberculosis triage testing... -
CHAARM Combined Highly Active Anti-retroviral Microbicides -
COBRA Co-morbidity in relation to AIDS -
Corporate ART Access Programs PharmAccess HIV Program -
DI-DIDA Digital Innovations and Diagnostics for Infectious Diseases in Africa -
Does POI predict POD? Does POI predict POD following BCG? -
EACCR III Eastern African Consortium for Clinical Research III -
EAPoC-VL Use of point-of-care HIV viral load monitoring to improve viral... -
EHVA European HIV Vaccine Alliance (EHVA): a EU platform for the... -
END-VOC European and Global Response to COVID-19 pandemic and variants of... -
EpiGen Ethiopia Genomic epidemiology for surveillance and control of poverty-related and emerging/re-emerging... -
Evolve Protecting Pyrazinamide and Fluoroquinolones for successful multi-drug resistant tuberculosis (MDR-TB)... -
GAPS Determining the gaps in the social science field of epidemic... -
H-TEAM HIV Transmission Elimination Amsterdam -
HALT_COVID-19 Natural History and Laboratory Tests for COVID-19 in South Africa -
HCV Study Assessing the incremental cost-effectiveness of a hypothetical introduction of a... -
HIP HOOKVAC India Partnership -
HOOKVAC Developing and testing a novel, low-cost, effective HOOKworm VACcine to... -
IBUA TB Improving TB case detection in a rural population by linkage... -
IMPALA An Innovative Monitoring system for PAediatrics in Low-resource settings: an... -
INDIGO Development of novel influenza vaccine in the EU, India, and... -
INSPIRE Impact of Non-B HIV-1 Subtype on second line Protease Inhibitor... -
INTERACT Infectious diseases Network for Treatment and Research in Africa -
M-PACT New challenge for HIV in Africa; exacerbated immune activation during... -
MARCH Monitoring Antiretroviral Resistance in Children -
MaxART Ending New Infection in Swaziland Phase II -
MC FREE Amsterdam MSM Hepatitis C Free -
Microbicides For phase III vaginal microbicide trials in Rwanda and Kenya:... -
NEAT 001 / ANRS 143 The European AIDS Treatment Network -
NOVOVAC Towards a novel, effective, low-cost Schistosomiasis vaccine for control of... -
ORIO Ghana Evaluating the impact of adding CAD4TB to symptom screening for... -
PASER Pan-African Studies to Evaluate Resistance -
PreFIT PreFit’s aim is to validate diagnostic prediction assays used at... -
PROMPT Prevention of early mortality by presumptive tuberculosis treatment in HIV... -
RapidProfiling SARS-CoV-2 Rapid diagnostic profiling of SARS-CoV-2 in the context of persistent... -
ROTA-biotic measuring the impact of rotavirus vaccines on pediatric antibiotic usage -
Rotabiome The influence of the intestinal microbiome on infant rotavirus vaccine... -
SALIF Switching At Low HIV-1RNA Into Fixed dose combinations -
Shinyanga Shinyanga HIV Test & Treat Project -
SoNAR-Global A Global Social Sciences Network for Infectious Threats and Antimicrobial... -
SPIN Novel strategies and tools for antimicrobial resistance surveillance -
SS4CE-HA Social Science for Community Engagement in Humanitarian Action Capacity Mapping -
SSNSS South Sudan Nodding Syndrome Study -
Stool4TB Evaluating a new stool based qPCR for diagnosis of tuberculosis... -
TAPS Expanded use of ART for treatment and prevention in female... -
TB IRIS Pathogenesis and identification of predictive factors of TB-IRIS in HIV... -
TB Targets Can we reach the post-2015 Targets in China, South Africa... -
TECoARTe Epidemiology and control of tuberculosis in the antiretroviral therapy era:... -
TESA II Trials of Excellence for Southern Africa -
TRiAD Triage Test for All Oral Drug Resistant Tuberculosis Regimen: T2RiAD... -
VALUE TB Cost-effectiveness of two new shortened (4-month) regimens replacing either E... -
Yellow4FLAVI Dissecting YF17D immunogenicity for more general vaccine design